Nature, Published online: 21 May 2025; doi:10.1038/s41586-025-08997-x

A population of TRAIL-positive astrocytes in glioblastoma contributes to an immunosuppressive tumour microenvironment and this mechanism can be targeted with an engineered oncolytic virus to improve outcomes.